Allergan Inc. Announces FDA Approves Revised Indication For OZURDEX ® (Dexamethasone Intravitreal Implant) 0.7 Mg For The Treatment Of Diabetic Macular Edema

IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc., (NYSE: AGN) announced today that the U.S. Food and Drug Administration (FDA) has approved OZURDEX® (dexamethasone intravitreal implant) 0.7 mg, a sustained-release biodegradable steroid implant, for the treatment of diabetic macular edema (DME). OZURDEX® was originally approved in June as a treatment for DME in adult patients who have an artificial lens implant (pseudophakic) or who are scheduled for cataract surgery (phakic). Based on ongoing review of clinical data demonstrating efficacy and safety, the FDA has now approved OZURDEX® for use in the general DME patient population.

Help employers find you! Check out all the jobs and post your resume.